Europe looks to shore up global competitiveness with the E.U. Biotech Act

The article examines how the E.U. Biotech Act addresses Europe’s competitive challenges in biotech by streamlining clinical trial approvals, introducing regulatory sandboxes for emerging technologies, and anchoring evidence generation within Europe through incentives like supplementary protection certificate extensions. It frames the Act as a strategic response to a decade of declining global competitiveness in life sciences innovation.